Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.67.

A number of analysts have commented on PLYX shares. Wall Street Zen raised Polaryx Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Zacks Research raised Polaryx Therapeutics to a “hold” rating in a report on Friday, July 10th. Weiss Ratings reissued a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th. HC Wainwright initiated coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Raymond James Financial assumed coverage on shares of Polaryx Therapeutics in a research note on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target for the company.

Polaryx Therapeutics Trading Down 4.3%

PLYX opened at $2.00 on Friday. Polaryx Therapeutics has a 1-year low of $1.85 and a 1-year high of $48.91. The company has a market cap of $99.70 million and a price-to-earnings ratio of -25.00. The company’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $3.17.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. As a group, equities analysts forecast that Polaryx Therapeutics will post -0.22 earnings per share for the current fiscal year.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.